Marengo Sees Broad Tumor Shrinkage
I denne episoden
- Marengo Sees Broad Tumor Shrinkage
- Alnylam Plans Huntington's Trial
- BMS Reports Zola-Cel Death
- Tango Advances Pancreatic Program
Kilder
- BioSpace: ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
- BioSpace: Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
- BioSpace: BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
- BioSpace: ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.